GSK claps back at Teva in 'skinny' label case, arguing verdict doesn't threaten companies who act 'properly'

A $235 million judgement against Teva in a case against GSK isn’t part of a run-of-the-mill patent dispute.

To generic drugmakers, the verdict is a threat to their ability to bring products to the market that have “skinny” labels—those that restrict a generic drug’s use to indications for which the branded product’s patents have expired.